NCT00772954 - Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions

Clostridium Difficile InfectionClostridium Difficile Diarrhea

Interventions

BIOLOGICAL

Vaccine diluent buffer

0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.

BIOLOGICAL

Clostridium difficile toxoid vaccine (50 μg)

0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.

BIOLOGICAL

Clostridium difficile toxoid vaccine (100 μg)

0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.